PIK3CA Mutation in HPV-Associated OPSCC Patients Receiving Deintensified Chemoradiation

Brian T. Beaty, Dominic H. Moon, Colette J. Shen, Robert J. Amdur, Jared Weiss, Juneko Grilley-Olson, Shetal Patel, Adam Zanation, Trevor G. Hackman, Brian Thorp, Jeffrey M. Blumberg, Samip N. Patel, Mark C. Weissler, Wendell G. Yarbrough, Nathan C. Sheets, Joel S. Parker, D. Neil Hayes, Karen E. Weck, Lori A. Ramkissoon, William M. MendenhallRoi Dagan, Xianming Tan, Gaorav P. Gupta, Bhishamjit S. Chera

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

PIK3CA is the most frequently mutated gene in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Prognostic implications of such mutations remain unknown. We sought to elucidate the clinical significance of PIK3CA mutations in HPV-associated OPSCC patients treated with definitive chemoradiation (CRT). Seventy-seven patients with HPV-associated OPSCC were enrolled on two phase II clinical trials of deintensified CRT (60 Gy intensity-modulated radiotherapy with concurrent weekly cisplatin). Targeted next-generation sequencing was performed. Of the 77 patients, nine had disease recurrence (two regional, four distant, three regional and distant). Thirty-four patients had mutation(s) identified; 16 had PIK3CA mutations. Patients with wild-type-PIK3CA had statistically significantly higher 3-year disease-free survival than PIK3CA-mutant patients (93.4%, 95% confidence interval [CI] = 85.0% to 99.9% vs 68.8%, 95% CI = 26.7% to 89.8%; P = .004). On multivariate analysis, PIK3CA mutation was the only variable statistically significantly associated with disease recurrence (hazard ratio = 5.71, 95% CI = 1.53 to 21.3; P = .01). PIK3CA mutation is associated with worse disease-free survival in a prospective cohort of newly diagnosed HPV-associated OPSCC patients treated with deintensified CRT.

Original languageEnglish (US)
Pages (from-to)855-858
Number of pages4
JournalJournal of the National Cancer Institute
Volume112
Issue number8
DOIs
StatePublished - Aug 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'PIK3CA Mutation in HPV-Associated OPSCC Patients Receiving Deintensified Chemoradiation'. Together they form a unique fingerprint.

  • Cite this

    Beaty, B. T., Moon, D. H., Shen, C. J., Amdur, R. J., Weiss, J., Grilley-Olson, J., Patel, S., Zanation, A., Hackman, T. G., Thorp, B., Blumberg, J. M., Patel, S. N., Weissler, M. C., Yarbrough, W. G., Sheets, N. C., Parker, J. S., Neil Hayes, D., Weck, K. E., Ramkissoon, L. A., ... Chera, B. S. (2020). PIK3CA Mutation in HPV-Associated OPSCC Patients Receiving Deintensified Chemoradiation. Journal of the National Cancer Institute, 112(8), 855-858. https://doi.org/10.1093/jnci/djz224